

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Norbert O. Reich et al. Examiner: James O. Wilson  
Serial No.: Not yet assigned Group Art Unit: 1623  
Filed: December 7, 2001 Docket: G&C 30794.30-US-D1  
Title: MODULATORS OF DNA CYTOSINE-5 METHYLTRANSFERASE AND  
METHODS FOR USE THEREOF

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on March 19, 2002.

By: 

Name: Karen S. Canady

REQUEST FOR TRANSFER OF SEQUENCE INFORMATION  
UNDER 37 CFR §1.821(e)

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

The paper copy of the Sequence Listing provided with the instant divisional application, filed December 7, 2001, is identical to the paper and computer readable copies of the Sequence Listing filed in parent application serial no. 09/485,071, filed on February 3, 2000, which corresponds to PCT application US98/12351 filed June 12, 1998. In accordance with 37 CFR §1.821(e), please use the first (and only) filed computer readable form filed in the parent application, as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the instant application.

Respectfully submitted,

GATES & COOPER LLP  
Attorneys for Applicant(s)  
Howard Hughes Center  
6701 Center Drive West, Suite 1050  
Los Angeles, California 90045  
(310) 641-8797

By: 

Name: Karen S. Canady  
Reg. No.: 39,927

Date: March 19, 2002

KSC/sjm  
G&C 30794.30-US-D1

G&C 30794.30-US-D1

REVIEWS  
FEB 04 2002



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
Gates & Cooper LLP  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/010,476	12/07/2001	Norbert O. Reich	O&C 30794.30-US-D1

CONFIRMATION NO. 8266

## FORMALITIES LETTER



\*OC000000007385075\*

Attn: Karen S. Canady  
Gates & Cooper LLP  
Howard Hughes Center  
6701 Center Drive West, Suite 1050  
Los Angeles, CA 90045

Date Mailed: 01/29/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

148

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE